CytoTools : Invest_Yorkville

• After securing the financing of the European clinical trials for the wound healing substance DermaPro®, they will start in the coming weeks
• Batches for the clinical trials will be produced by chemists from DermaTools in the production facilities in India
• The new American investor, Yorkville Advisors Global, LP, provides a long- term financing commitment

-

CytoTools AG has secured the necessary financial means for the repeat of the clinical trials by issuing convertible bonds with an American institutional investor managed by Yorkville Advisors Global, LP ("Yorkville"). The completed agreement allows, within the next three years, the issue of convertible bonds with an overall nominal value of EUR 15 mill. Yorkville is a globally active investment management company for specialized financing solutions for listed stock corporations. The Healthcare Division of Yorkville, headed by the company Managing Director Saad Gilani, invests in a wide range of life science enterprises in the USA and Europe, specializing in biotechnology, molecular diagnostics, surgical instruments and medical products.

Within Europe, Gilani's geographical investment focus is on Germany, France, Switzerland and Great Britain. "In Germany, we have already invested in several stock market-listed life science enterprises and CytoTools suits our portfolio ideally. We are pleased to provide financing to help support the implementation of CytoTools' business plan in Europe": Saad Gilani commented.

"We believe that this investment underlines the high potential of our active substance DermaPro®", commented the CytoTools AG CEO, Dr. Mark-Andre Freyberg. "Now that we have already received market approval for India under certain production provisions, for the successful treatment possibility of diabetic foot - the most serious chronic wound - our next step is market maturity in Europe. Looking back, 2017 was a year of important milestones which have provided the basis for a future substantial growth of the CytoTools AG."

This press release contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future- oriented statements made. CytoTools is not obligated to update these future-oriented statements.

CytoTools AG, previously CytoTools GmbH, is a technology holding and participating company which holds shares in its subsidiary companies with product developments in the pharmaceutical and medical products fields: about ca. 57 % of the DermaTools Biotech GmbH (therapy field dermatology, urology) and 42 % of the CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide and which are transferred to the subsidiary companies in the form of worldwide exclusive licenses

Yorkville (Mountainside, New Jersey; USA), is a globally active investment manager for specialized financing solutions for listed stock corporations. The Healthcare Division of Yorkville, headed by Managing Director Saad Gilani, invests in a wide range of life science enterprises in the USA and Europe, specializing in biotechnology, molecular diagnostics, surgical instruments and medical products.

CytoTools AG

Dr. Mark Andre Freyberg Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: freyberg@cytotools.de